Indian Covid-19 vaccine Covaxin triggered immune response, finds Phase 1 trial
Indian Covid-19 vaccine Covaxin triggered immune response, no serious adverse effects, finds Phase 1 trial.
Hyderabad-based Bharat Biotech, developers of Covaxin on Wednesday said the vaccine induces an immune response and registered no serious adverse events, reports the NDTV.
The vaccine "induced (a) neutralising antibody (an immune response)" and was "well-tolerated in all dose groups with no vaccine-related serious adverse events", the company said.
Keep updated, follow The Business Standard's Google news channel
"After the first vaccination, local and systemic adverse events were predominantly mild or moderate in severity and resolved rapidly, without any prescribed medication. The most common adverse event was pain at the injection site, which resolved spontaneously," it added.
Covaxin is one of three vaccine candidates that has applied to the Indian government for emergency use authorisation.
